A Study to Compare SB12 (Proposed Eculizumab Biosimilar) to Soliris in Subjects With Paroxysmal Nocturnal Haemoglobinuria

NCT04058158 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Paroxysmal Nocturnal Hemoglobinuria

Interventions

DRUG: SB12 (proposed eculizumab biosimilar)
DRUG: Soliris (eculizumab)

Sponsor

Samsung Bioepis Co., Ltd.